Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- 13 April 2016
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 60, 190-209
- https://doi.org/10.1016/j.ejca.2016.02.025
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- Ipilimumab associated hepatitis: imaging and clinicopathologic findingsInvestigational New Drugs, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals Of Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Anti-CTLA4 Antibody–Induced Lupus NephritisNew England Journal of Medicine, 2009
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007